Wells Fargo reiterated coverage on Adaptimmune Therapeutics with a new price target
$ADAP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wells Fargo reiterated coverage of Adaptimmune Therapeutics with a rating of Equal-Weight and set a new price target of $7.00 from $6.00 previously